ISPOR Europe 2023

SA17: Application of CPRD Data in NICE Submissions: Model Inputs for Functional Health States

Session Time: 10:30-13:30  |  Discussion Hour: 12:30-13:30

---

HTA34: Demonstrating Similar or Greater Health Benefits Based on Indirect Evidence: A Review of NICE Evaluations that Include a Cost-Comparison Approach

Session Time: 10:30-13:30  |  Discussion Hour: 12:30-13:30

---

HTA7: Exploring The Predictive Accuracy of Treatment Waning Methods: An Analysis of Pembrolizumab Across Six Oncology Indications

Session Time: 10:30-13:30  |  Discussion Hour: 12:30-13:30

---

MSR53: Flexsurv Methods to Estimate CuRe: An Exploration of Methods for Modelling Cure

Session Time: 15:30-18:30  |  Discussion Hour: 16:00-17:00

---

HTA132: Reporting Patient Preference Studies in HTA Submissions: Does it Make a Difference?

Session Time: 15:30-18:30  |  Discussion Hour: 16:00-17:00

---

EE198: A Targeted Literature Review of Treatment Sequencing Approaches in Economic Analyses in Relapsing Multiple Sclerosis

Session Time: 15:30-18:30  |  Discussion Hour: 16:00-17:00

---

HTA112: The NICE Medical Technologies Evaluation Program: An Analysis of Clinical and Economic Evidence Evaluated in Published Medical Technology Guidance

Session Time: 15:30-18:30  |  Discussion Hour: 16:00-17:00

 

HTA193: Benefits Not Captured in the Quality-Adjusted Life Year Calculation: What Role Do They Play in the National Institute for Health and Care Excellence’s Updated Decision-Making Process?

Session Time: 10:30-13:30  |  Discussion Hour: 12:30-13:30

 

HTA327: Acceptance of Real-World Evidence as Comparative Efficacy in Lieu of Trial Evidence: A Review of Past NICE Appraisals in Oncology

Session Time: 9:00-11:30  |  Discussion Hour: 9:00-10:00